City of Hope, Duarte
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07226843

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

City of Hope Medical Center, Duarte
City of Hope Orange County Lennar Foundation Cancer Center, Irvine

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06453044

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

City of Hope, Duarte

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07101328

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Research Site, Clovis
Research Site, Los Alamitos
Research Site, San Diego
и уште 1

Се регрутираФаза 3

Возраст од 18 до 130 · Сите полови · Ажурирано 21.9.2026 · NCT06549595

NEO100 and High-Grade Meningioma

University of Southern California, Los Angeles
Sutter Health Research Institute, San Francisco
Saint John Cancer Institute, Santa Monica

Се регрутираФаза 2

Возраст 12 и постари · Сите полови · Ажурирано 15.9.2026 · NCT05023018

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Research Site, Duarte

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT06526793

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

David Geffen School of Medicine at UCLA, Los Angeles

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT06091254

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

City of Hope Comprehensive Cancer Center, Duarte
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC San Diego Moores Cancer Center, La Jolla
и уште 2

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 2.9.2026 · NCT06860594

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Research Site, Rialto

Се регрутираФаза 1Добредојдени се здрави волонтери

Возраст од 18 до 85 · Сите полови · Ажурирано 1.9.2026 · NCT07546760

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

University of California San Diego, La Jolla
University of California, Los Angeles, Los Angeles
Hoag Memorial Hospital Presbyterian, Newport Beach
и уште 2

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 28.8.2026 · NCT05303519

A Study of ARC-02 in B-cell NHL

Start Cala, Los Angeles

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 26.8.2026 · NCT07691606

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

University of California-Irvine Medical Center, Irvine
Cedars-Sinai Medical Center, Los Angeles
University of California, Los Angeles (UCLA) Medical Center, Los Angeles
и уште 1

Се регрутираФаза 1/2

Возраст 18 и постари · Сите полови · Ажурирано 25.8.2026 · NCT05826535

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

David Geffen School of Medicine at UCLA, Los Angeles

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 14.8.2026 · NCT06149286

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 12.8.2026 · NCT06340737

Interventions in Mathematics and Cognitive Skills

Stanford Cognitive and Systems Neuroscience Laboratory, Palo Alto

Се регрутираДобредојдени се здрави волонтери

Возраст од 6 до 12 · Сите полови · Ажурирано 11.8.2026 · NCT05201534

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

Се регрутираФаза 1/2

Возраст од 13 до 90 · Сите полови · Ажурирано 6.8.2026 · NCT06533579

STimulation to Activate RespIration

University of California San Diego, La Jolla

Се регрутира

Возраст 18 и постари · Сите полови · Ажурирано 6.8.2026 · NCT06832306

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

START Los Angele, Los Angeles

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 30.7.2026 · NCT07424833

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

City of Hope, Duarte

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 24.7.2026 · NCT07121946

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte
University of California, San Francisco, San Francisco

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 2.7.2026 · NCT05131022

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

University of California Davis Comprehensive Cancer Center, Sacramento

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 29.6.2026 · NCT04587687

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

City of Hope Medical Center, Duarte

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 29.6.2026 · NCT06815029

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 22.6.2026 · NCT04545762

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

City of Hope Comprehensive Cancer Center, Duarte
UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 20.5.2026 · NCT06911502

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 20.4.2026 · NCT06859008

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

City of Hope, Duarte
Los Angeles Cancer Network, Los Angeles
UCLA Medical Center of Hematology/Oncology, Los Angeles
и уште 1

Се регрутираФаза 1/2

Возраст од 12 до 95 · Сите полови · Ажурирано 15.4.2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 20.3.2026 · NCT04830137

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

Stanford, Stanford

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 13.3.2026 · NCT06510361

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

UC Irvine Health, Orange

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 10.12.2025 · NCT05602363

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Duarte
Massive Bio SYNERGY-AI site, Irvine
Massive Bio SYNERGY-AI site, La Jolla
и уште 3

Се регрутираНабљудувачка студија

Сите возрасти · Сите полови · Ажурирано 28.10.2025 · NCT03452774

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Stanford Cancer Center, Palo Alto

Се регрутираНабљудувачка студија

Возраст 18 и постари · Сите полови · Ажурирано 22.8.2024 · NCT05255354

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.